Recently, the use of PDEδ inhibitors has been proposed as anticancer agents because they interrupted KRas signaling leading to antiproliferative effects in KRas-dependent pancreatic cancer cells. The gene discussed is PDE6D; the disease is familial pancreatic carcinoma.